116 related articles for article (PubMed ID: 12543792)
41. Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.
Horiguchi A; Chen DY; Goodman OB; Zheng R; Shen R; Guan H; Hersh LB; Nanus DM
Prostate Cancer Prostatic Dis; 2008; 11(1):79-87. PubMed ID: 17563767
[TBL] [Abstract][Full Text] [Related]
42. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A.
Zheng JY; Chen D; Chan J; Yu D; Ko E; Pang S
Cancer Gene Ther; 2003 Oct; 10(10):764-70. PubMed ID: 14502229
[TBL] [Abstract][Full Text] [Related]
43. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
44. A role for the WWOX gene in prostate cancer.
Qin HR; Iliopoulos D; Semba S; Fabbri M; Druck T; Volinia S; Croce CM; Morrison CD; Klein RD; Huebner K
Cancer Res; 2006 Jul; 66(13):6477-81. PubMed ID: 16818616
[TBL] [Abstract][Full Text] [Related]
45. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
Weng JR; Tsai CH; Kulp SK; Wang D; Lin CH; Yang HC; Ma Y; Sargeant A; Chiu CF; Tsai MH; Chen CS
Cancer Res; 2007 Aug; 67(16):7815-24. PubMed ID: 17699787
[TBL] [Abstract][Full Text] [Related]
46. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.
Bandyopadhyay A; Wang L; López-Casillas F; Mendoza V; Yeh IT; Sun L
Prostate; 2005 Apr; 63(1):81-90. PubMed ID: 15468171
[TBL] [Abstract][Full Text] [Related]
47. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
[TBL] [Abstract][Full Text] [Related]
48. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
49. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4.
Heideman DA; van Beusechem VW; Bloemena E; Snijders PJ; Craanen ME; Offerhaus GJ; Derksen PW; de Bruin M; Witlox MA; Molenaar B; Meijer CJ; Gerritsen WR
J Gene Med; 2004 Mar; 6(3):317-27. PubMed ID: 15026993
[TBL] [Abstract][Full Text] [Related]
50. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model.
Lin SH; Pu YS; Luo W; Wang Y; Logothetis CJ
Anticancer Res; 1999; 19(1A):337-40. PubMed ID: 10226564
[TBL] [Abstract][Full Text] [Related]
51. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
52. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
Isayeva T; Chanda D; Kallman L; Eltoum IE; Ponnazhagan S
Cancer Res; 2007 Jun; 67(12):5789-97. PubMed ID: 17575146
[TBL] [Abstract][Full Text] [Related]
53. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
[TBL] [Abstract][Full Text] [Related]
54. [Inhibition of tumor growth and metastasis via local administration of recombinant human endostatin adenovirus].
Wu Y; Yang L; Zhao X; Su JM; Hu B; Liu JY; Niu T; Luo Y; Li Q; Wei YQ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Dec; 21(6):557-61. PubMed ID: 15583981
[TBL] [Abstract][Full Text] [Related]
55. Adenovirus carrying TIMP-3: a potential tool for cervical cancer treatment.
Zhang Y; Qian H; Lin C; Lang J; Xiang Y; Fu M; Zhang X; Liang X
Gynecol Oncol; 2008 Jan; 108(1):234-40. PubMed ID: 17976707
[TBL] [Abstract][Full Text] [Related]
56. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
[TBL] [Abstract][Full Text] [Related]
57. The cytoplasmic domain of C-CAM1 tumor suppressor is necessary and sufficient for suppressing the tumorigenicity of prostate cancer cells.
Estrera VT; Luo W; Phan D; Earley K; Hixson DC; Lin SH
Biochem Biophys Res Commun; 1999 Oct; 263(3):797-803. PubMed ID: 10512760
[TBL] [Abstract][Full Text] [Related]
58. Canstatin gene electrotransfer combined with radiotherapy: preclinical trials for cancer treatment.
Magnon C; Opolon P; Connault E; Mir LM; Perricaudet M; Martel-Renoir D
Gene Ther; 2008 Nov; 15(21):1436-45. PubMed ID: 18548116
[TBL] [Abstract][Full Text] [Related]
59. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy.
Okegawa T; Li Y; Pong RC; Bergelson JM; Zhou J; Hsieh JT
Cancer Res; 2000 Sep; 60(18):5031-6. PubMed ID: 11016624
[TBL] [Abstract][Full Text] [Related]
60. Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein.
Caceres G; Dauphinee MJ; Eisele LE; MacColl R; Mizejewski GJ
Anticancer Res; 2002; 22(5):2817-20. PubMed ID: 12530002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
